Navigation Links
Access Pharmaceuticals Receives Letter of Acceptance For MuGard Filing From SFDA of China
Date:6/17/2011

r additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.Contact: Company

Contact: Investor RelationsChristine Berni

Donald C. Weinberger/Diana Bittner (media)Director of Investor Relations

Wolfe Axelrod Weinberger Assoc. LLCAccess Pharmaceuticals, Inc.

(212) 370-4500(212) 786-6208
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... Inc. (NYSE Amex: ANX ) today announced that ... at the 10th Annual BIOInvestor Forum Conference on Wednesday, October ... Cliff Salon at the Palace Hotel in San Francisco. ... and slide presentation on the ADVENTRX Pharmaceuticals web site at ...
... Innocoll, Inc. announced it has entered into a ... for CollaGUARD surgical adhesion barrier for the prevention of ... Dr. Michael Myers, President and CEO stated "This ... an increasingly important and dynamic market for medical products ...
Cached Medicine Technology:Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD 2Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD 3
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
(Date:4/17/2014)... (SACRAMENTO, Calif.) An international team led by researchers ... protein complex, which plays a key role in cell ... process. This is the first time the complex has ... could make cyclin B1/Cdk1 an excellent target to control ... medicine. The research was published online today in the ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
(Date:4/17/2014)... to find a colored ribbon representing a disease. A pink ... color ribbon does one think of with lung cancer?, Although ... suffering from the disease, black may be the only one ... lung cancer patients, primarily smokers between the ages of 51 ... stigma often felt by these patients, the emotional toll it ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... news service, along,with its production and distribution partner, NewsProNet, ... to give viewers a daily update on the,latest medical ... Each weekday starting in January 2009, HealthDay TV ... Medical Officer Dr. Cynthia,Haines, who will give insight into ...
... (ECMO) Center at University Hospitals Rainbow Babies & ... Support Award from the Extracorporeal Life Support Organization ... centers offering ECMO for support of failing organ ... award recognizes centers demonstrating an exceptional commitment to ...
... Dec. 2 New research that delivers a,wealth of ... and,manufacturing is now available in the Best Practice Database, ... Best Practices,LLC. , ... these,pharmaceutical-focused studies, go to a landing page with links ...
... Cantel Medical Corp. (NYSE: CMN ) will hold ... first quarter ended October 31, 2008 on December 5, 2008 ... be Charles M. Diker, Chairman; Andrew A. Krakauer, President; Craig ... Malkin, President of Minntech Corporation. Minntech is a Cantel subsidiary. ...
... 2 Ingenious Med (IM) welcomes new CEO, S.,Hart ... solutions, with an extensive background as a leader in ... , Founder and ... the company,s success and development in all sectors, as ...
... it in first 3 months more likely to have respiratory ... mothers take folic acid (folate) during early pregnancy may have ... study. , Folate is recommended to reduce the risk of ... acid. , The researchers examined data on more than 32,000 ...
Cached Medicine News:Health News:HealthDay TV Launches 2Health News:HealthDay TV Launches 3Health News:Best Practice Database Adds Research Highlighting Effective Tactics of Sales Force and Manufacturing Groups in the Pharmaceutical Industry 2Health News:Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its First Quarter Ended October 31, 2008 2Health News:Ingenious Med Hires New CEO to Maintain and Further Expand Company Development 2Health News:Folate in Early Pregnancy May Boost Wheezing in Baby 2
... intra-operative MR system is ... tool for radiologists and ... of the system is ... adjunct to standard neurosurgical ...
... Adhesive (Bioglue) is a two-component surgical ... albumin (BSA) and glutaraldehyde. The BSA ... bovine spongiform encephalopathy (BSE) free countries ... inactivates viruses. The solutions are dispensed ...
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical...
... Prodisc design is based upon the ... natural spinal motion segment unit. Kinematics ... integrates the biomechanical and anatomical aspects ... concept: Three implant components utilizing proven ...
Medicine Products: